Compare GSK plc (GSK) vs Nutanix Inc (NTNX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Nutanix Inc — how do they compare? GSK plc trades at $50.26 (market cap $102.60B), while Nutanix Inc trades at $64.65 (market cap $17.39B). The key difference: GSK plc is far larger — about 5.9× Nutanix Inc's market cap, and GSK plc pays a 3.57% dividend while Nutanix Inc pays none. Which is the better fit depends on your goals.
| GSK | NTNX | |
|---|---|---|
Market Cap | $102.60B | $17.39B |
Sector | Health | Technology |
52-Week High | $61.18 | $81.12 |
52-Week Low | $38.96 | $34.41 |
Enterprise Value | $123.04B | $16.90B |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
Nutanix (NTNX) trades at $64.65, up 0.29% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with Q1 2026 EPS beating expectations at $0.47 versus $0.36, maintaining a streak of earnings surprises. Revenue growth accelerated to $2.7B in 2026 with net profit margin expanding to 10.03%, while institutional interest remains strong with recent acquisitions by Arrowstreet Capital and CalPERS.
Outlook remains positive with 62.5% analyst buy ratings and a $57.80 consensus target, though current price exceeds this level. Key risks include supply chain constraints affecting hardware lead times and competitive pressure in cloud infrastructure. The stock's elevated P/E of 67.71 requires continued execution to justify valuation, with Q2 2026 earnings on August 26th serving as near-term catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →
